Related Experiment Video
Updated: Dec 5, 2025
08:41
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
3.1K
Deciphering Vaccines for COVID-19: where do we stand today?
Tushar Baviskar1, Dezaree Raut1, Lokesh Kumar Bhatt1
1Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India.
Immunopharmacology and Immunotoxicology
|October 15, 2020
Summary
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a pandemic affecting over 200 nations. This review covers global vaccine development platforms and candidate statuses to combat the virus.
Area of Science:
- * Virology and Immunology
- * Global Health and Epidemiology
Background:
- * The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, led to the COVID-19 pandemic.
- * COVID-19 has impacted over 200 countries, with significant effects in the USA, India, Brazil, Russia, and Peru.
- * Understanding SARS-CoV-2's genotype and phenotype is crucial for developing effective treatments and vaccines.
Purpose of the Study:
- * To review global vaccine development platforms and technologies for COVID-19.
- * To provide an overview of the current status of COVID-19 vaccine candidates.
- * To highlight efforts in combating the global COVID-19 pandemic through vaccination.
Main Methods:
- * Comprehensive literature review of scientific publications and reports on COVID-19 vaccine development.
- * Analysis of various vaccine platforms, including mRNA, viral vector, inactivated virus, and protein subunit vaccines.
- * Assessment of the progress and status of leading vaccine candidates from global organizations.
Main Results:
- * Multiple vaccine platforms are being employed globally, demonstrating diverse technological approaches.
- * Several vaccine candidates have advanced to various stages of clinical trials.
- * The rapid progression of vaccine development signifies a concerted global effort against the pandemic.
Conclusions:
- * The development of effective vaccines is essential to control the rapid transmission of SARS-CoV-2.
- * Ongoing research and collaboration are accelerating the availability of diverse COVID-19 vaccines.
- * Vaccination remains a critical strategy in mitigating the impact of the global COVID-19 pandemic.
Related Concept Videos
01:51Vaccinations
50.2K
Overview
50.2K
01:30Cancer Vaccines
837
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
837
01:29Microorganisms in Medicine and Therapeutics
744
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
744
01:11Clinical Trials: Overview
4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
01:26FDA Approved Drugs: Changes to Approved Drugs
106
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
106
02:50Conjugated Proteins
24.7K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
24.7K